Exagen (XGN) Gains from Investment Securities (2018 - 2026)

Exagen's (XGN) quarterly Gains from Investment Securities came in at -$882000.0 in Q1 2026, up 44.94% on a QoQ basis from -$1.6 million in Q4 2025.

Exagen (XGN) Gains from Investment Securities (2018 - 2026) Analysis & Trends

Exagen (XGN) has 4 years of Gains from Investment Securities data on file, last reported at -$882000.0 in Q1 2026.

Quarterly Gains from Investment Securities changed N/A year-over-year to -$882000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $624000.0 (changed N/A YoY) and the FY2025 annual result came in at $1.5 million, changed N/A from the prior year.
Gains from Investment Securities improved to -$882000.0 in Q1 2026, from -$1.6 million in the prior quarter.
In the past five years, Gains from Investment Securities ranged from a high of $2.7 million in Q3 2025 to a low of -$1.6 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Thermo Fisher Scientific	213.88 Bn	209.81 Bn	8.34 Bn
2	Danaher	140.65 Bn	136.30 Bn	3.61 Bn
3	Idexx Laboratories	46.02 Bn	45.83 Bn	779.09 Mn
4	Agilent Technologies	39.85 Bn	38.05 Bn	990.00 Mn
5	Iqvia Holdings	39.20 Bn	37.12 Bn	1.44 Bn
6	Natera	38.80 Bn	37.70 Bn	696.04 Mn
7	Illumina	30.11 Bn	28.94 Bn	770.00 Mn
8	Mettler Toledo International	28.66 Bn	28.61 Bn	650.22 Mn
9	Quest Diagnostics	26.24 Bn	25.61 Bn	1.03 Bn
10	Exagen	158.28 Mn	133.68 Mn	12.22 Mn

Download Data